[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyondspring Inc (BYSI)

Beyondspring Inc (BYSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,203
  • Shares Outstanding, K 41,120
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,010 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow 14.21
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 341.18% (+103.01%)
  • Historical Volatility 73.97%
  • IV Percentile 90%
  • IV Rank 69.44%
  • IV High 478.87% on 06/18/26
  • IV Low 28.25% on 11/20/25
  • Expected Move (DTE 23) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 12
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 422
  • Open Int (30-Day) 393
  • Expected Range 1.6450 to 1.6450

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4300 +15.03%
on 05/28/26
1.7700 -7.06%
on 06/04/26
+0.0750 (+4.78%)
since 05/22/26
3-Month
1.1750 +40.00%
on 05/19/26
1.8400 -10.60%
on 04/08/26
+0.0250 (+1.54%)
since 03/24/26
52-Week
1.1750 +40.00%
on 05/19/26
2.6200 -37.21%
on 06/27/25
-0.8050 (-32.86%)
since 06/24/25

Most Recent Stories

More News
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each...

BYSI : 1.6450 (+2.17%)
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival...

BYSI : 1.6450 (+2.17%)
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the...

BYSI : 1.6450 (+2.17%)
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular...

BYSI : 1.6450 (+2.17%)
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin’s...

BYSI : 1.6450 (+2.17%)
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for...

BYSI : 1.6450 (+2.17%)
BeyondSpring Files 2025 Annual Report on Form 10-K

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for...

BYSI : 1.6450 (+2.17%)
BeyondSpring Reports 2025 Year-End Financial Results

Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care...

BYSI : 1.6450 (+2.17%)
BeyondSpring Reports 2025 Year-End Financial Results

Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care...

BYSI : 1.6450 (+2.17%)
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today...

BYSI : 1.6450 (+2.17%)

Business Summary

BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced...

See More

Key Turning Points

3rd Resistance Point 1.8233
2nd Resistance Point 1.7617
1st Resistance Point 1.7033
Last Price 1.6450
1st Support Level 1.5833
2nd Support Level 1.5217
3rd Support Level 1.4633

See More

52-Week High 2.6200
Fibonacci 61.8% 2.0680
Fibonacci 50% 1.8975
Fibonacci 38.2% 1.7270
Last Price 1.6450
52-Week Low 1.1750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.